Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens:: role of 5-HT2A and α1-adrenoceptor antagonism

被引:33
作者
Marcus, MM [1 ]
Nomikos, GG [1 ]
Svensson, TH [1 ]
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden
关键词
nucleus accumbens; core; shell; in vivo voltammetry; dopamine; antipsychotic drugs;
D O I
10.1016/S0924-977X(00)00077-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The effects of acute intravenous administration of several new, atypical antipsychotic drugs (APDs): olanzapine (0.05 and 1.0 mg/kg), sertindole (0.1 and 1.0 mg/kg) and quetiapine (0.25 and 2.5 mg/kg), a selective 5-HT2A receptor antagonist, M100907 (0.03 and 0.3 mg/kg), and an alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg), on regional dopamine output were examined in the two subdivisions of the nucleus accumbens (NAC), the core and shell, which seem associated with motor control and limbic functions, respectively, by using in vivo differential normal pulse voltammetry in anaesthetised, pargyline-pretreated rats. Both quetiapine and sertindole, in the two doses used, caused a more pronounced dopamine release in the shell than in the core region of the NAC. In contrast, the low dose of olanzapine increased dopamine output almost to the same extent in both regions, whereas the high dose increased dopamine output to a greater extent in the core. M100907 selectively increased dopamine output in the shell. Also, prazosin significantly increased dopamine output in the shell, but not in the core. The results indicate that both 5-HT2A and alpha(1)-adrenoceptor antagonism may play an important role in the preferential effect of atypical APDs on dopamine output in the shell versus the core of the NAC. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:245 / 253
页数:9
相关论文
共 58 条
[21]   SPECIFICITY IN THE PROJECTION PATTERNS OF ACCUMBAL CORE AND SHELL IN THE RAT [J].
HEIMER, L ;
ZAHM, DS ;
CHURCHILL, L ;
KALIVAS, PW ;
WOHLTMANN, C .
NEUROSCIENCE, 1991, 41 (01) :89-125
[22]  
HOFFMAN B B, 1990, P221
[23]  
KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789
[24]  
Kehne JH, 1996, J PHARMACOL EXP THER, V277, P968
[25]   Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects [J].
Laruelle, M ;
Abi-Dargham, A ;
vanDyck, CH ;
Gil, R ;
DSouza, CD ;
Erdos, J ;
McCance, E ;
Rosenblatt, W ;
Fingado, C ;
Zoghbi, SS ;
Baldwin, RM ;
Seibyl, JP ;
Krystal, JH ;
Charney, DS ;
Innis, RB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (17) :9235-9240
[26]   INTERACTION OF ANTIPSYCHOTIC-DRUGS WITH NEUROTRANSMITTER RECEPTOR-SITES IN-VITRO AND IN-VIVO IN RELATION TO PHARMACOLOGICAL AND CLINICAL EFFECTS - ROLE OF 5HT(2) RECEPTORS [J].
LEYSEN, JE ;
JANSSEN, PMF ;
SCHOTTE, A ;
LUYTEN, WHML ;
MEGENS, AAHP .
PSYCHOPHARMACOLOGY, 1993, 112 (01) :S40-S54
[27]   Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens [J].
Marcus, MM ;
Nomikos, GG ;
Svensson, TH .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1996, 6 (01) :29-38
[28]  
MARDER SR, 1994, AM J PSYCHIAT, V151, P825
[29]   Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens [J].
Mathe, JM ;
Nomikos, GG ;
Hildebrand, BE ;
Hertel, P ;
Svensson, TH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 309 (01) :1-11
[30]  
Mathé JM, 1998, J NEUROSCI RES, V51, P583, DOI 10.1002/(SICI)1097-4547(19980301)51:5<583::AID-JNR5>3.0.CO